To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 1 mg

Bioavailability of Alprazolam Tablets

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00913341

Enrollment

Registered

2009-06-04

Start date

1991-11-30

Completion date

1991-11-30

Last updated

2017-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety

Brief summary

To demonstrate the relative bioavailability of Alprazolam tablets, 1 mg.

Interventions

DRUGAlprazolam Tablets, 1 mg (Geneva Pharmaceuticals)

DRUGAlprazolam Tablets, 1 mg (The Upjohn Company)

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

19 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion criteria

* Positive test results for HIV or hepatitis B or C. * Treatment for drug or alcohol dependence.

Design outcomes

Primary

Measure	Time frame
Bioequivalence based on AUC and Cmax	13 days

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026